OrbiMed’s Athenex, Inc. Common Stock ATNX Stock Holding History

OrbiMed’s Portfolio ATNX Stock Details ATNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-184,703	Closed	-$40.9M	–	183
2020 Q4	$40.9M	Sell	184,703 -14,195	-7%	-$3.49M	0.36%	67
2020 Q3	$48.1M	Sell	198,898 -1,569	-0.8%	-$377K	0.61%	53
2020 Q2	$55.2M	Hold	200,467	–	–	0.78%	41
2020 Q1	$31M	Buy	200,467 +61,856	+45%	+$15.6M	0.52%	53
2019 Q4	$42.3M	Sell	138,611 -26,835	-16%	-$7.09M	0.6%	50
2019 Q3	$40.3M	Sell	165,446 -26,561	-14%	-$8.68M	0.76%	43
2019 Q2	$76M	Buy	192,007 +170,507	+793%	+$47.3M	1.18%	28
2019 Q1	$5.27M	Hold	21,500	–	–	0.08%	106
2018 Q4	$5.46M	Hold	21,500	–	–	0.1%	99
2018 Q3	$6.68M	Hold	21,500	–	–	0.08%	122
2018 Q2	$8.02M	Hold	21,500	–	–	0.1%	116
2018 Q1	$7.31M	Buy	+21,500	New	+$6.82M	0.09%	111

Other funds holding ATNX

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

OrbiMed's ATNX Position: Q1 2021 in Review

OrbiMed sold out of Athenex, Inc. Common Stock (ATNX) in Q1 2021, closing a stake of 184,703 shares — an estimated $40.9M sold.

OrbiMed first reported a position in ATNX in Q1 2018 and held it in 12 quarters. The position peaked at $76M in Q2 2019. 122 funds tracked by Wall St. Rank hold ATNX as of Q1 2021.

OrbiMed reported no remaining Athenex, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
OrbiMed sold 184,703 Athenex, Inc. Common Stock shares in Q1 2021, an estimated $40.9M.
OrbiMed first reported a position in Athenex, Inc. Common Stock in Q1 2018 and held it in 12 quarters.
OrbiMed's Athenex, Inc. Common Stock position peaked at $76M in Q2 2019.
122 funds tracked by Wall St. Rank held Athenex, Inc. Common Stock as of Q1 2021.

Based on OrbiMed's 13F filing for Q1 2021, filed 17 May 2021.